Yanping P. Ma

382 Wuyi Road
Taiyuan, 030000, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 38 publications

Clinical Characteristics and Prognostic Analysis of Extramedullary Disease in Multiple Myeloma: A 15-Year Retrospective Cohort Study.

Clinical Characteristics and Prognostic Analysis of Extramedullary Disease in Multiple Myeloma: A 15-Year Retrospective Cohort Study.

Journal: Cancers

Published: June 20, 2026

A prospective, phase IV study of ixazomib, pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma.

A prospective, phase IV study of ixazomib, pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma.

Journal: British journal of haematology

Published: March 27, 2026

RAD23A promotes multiple myeloma cell survival through DNA damage response, proteostasis and enhanced metabolic activity.

RAD23A promotes multiple myeloma cell survival through DNA damage response, proteostasis and enhanced metabolic activity.

Journal: Toxicology and applied pharmacology

Published: March 20, 2026

Olverembatinib-Based Therapy in Patients With Transformed Chronic Myeloid Leukemia in Lymphoid Blast Phase or Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Multicenter Retrospective Study.

Olverembatinib-Based Therapy in Patients With Transformed Chronic Myeloid Leukemia in Lymphoid Blast Phase or Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Multicenter Retrospective Study.

Journal: Clinical lymphoma, myeloma & leukemia

Published: January 07, 2026

Development, reliability, and validity of a treatment-related quality of life scale for Chinese patients with multiple myeloma

Development, reliability, and validity of a treatment-related quality of life scale for Chinese patients with multiple myeloma

Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi

Published: October 14, 2025

Quadruplet daratumumab in combination with bortezomib, lenalidomide, and dexamethasone as front-line regimen improved clinical outcomes in high-risk myeloma patients in China: a multi-centered prospective real-world study.

Quadruplet daratumumab in combination with bortezomib, lenalidomide, and dexamethasone as front-line regimen improved clinical outcomes in high-risk myeloma patients in China: a multi-centered prospective real-world study.

Journal: BMC cancer

Published: September 30, 2025

Mendelian Randomization Analysis Reveals the Causal Relationships Between Autoimmune Diseases and Idiopathic Thrombocytopenic Purpura and the Mediating Role of Immune Cells.

Mendelian Randomization Analysis Reveals the Causal Relationships Between Autoimmune Diseases and Idiopathic Thrombocytopenic Purpura and the Mediating Role of Immune Cells.

Journal: European journal of rheumatology

Published: May 16, 2025

Olverembatinib in accelerated-phase chronic myeloid leukemia: efficacy and safety evaluation.

Olverembatinib in accelerated-phase chronic myeloid leukemia: efficacy and safety evaluation.

Journal: Haematologica

Published: May 15, 2025

DNA damage repair (DDR) related prognostic risk model in multiple myeloma based on single-cell and bulk sequencing.

DNA damage repair (DDR) related prognostic risk model in multiple myeloma based on single-cell and bulk sequencing.

Journal: DNA repair

Published: April 07, 2025

RPL29 as a radiotherapy-sensitive prognostic biomarker in multiple myeloma.

RPL29 as a radiotherapy-sensitive prognostic biomarker in multiple myeloma.

Journal: World journal of surgical oncology

Published: April 01, 2025

Optimizing olverembatinib dose in chronic phase chronic myeloid leukemia.

Optimizing olverembatinib dose in chronic phase chronic myeloid leukemia.

Journal: Haematologica

Published: December 04, 2024

Expert consensus on a multidisciplinary approach for the management of multiple myeloma-related bone disease.

Expert consensus on a multidisciplinary approach for the management of multiple myeloma-related bone disease.

Journal: Cancer pathogenesis and therapy

Published: September 02, 2024

Showing 1-12 of 38

Last Updated: 09/26/2026